EP4784121A1 - Pharmazeutische zusammensetzungen mit 5-methoxy-n,n-dimethyltryptamin (5-meo-dmt) - Google Patents

Pharmazeutische zusammensetzungen mit 5-methoxy-n,n-dimethyltryptamin (5-meo-dmt)

Info

Publication number
EP4784121A1
EP4784121A1 EP24787545.3A EP24787545A EP4784121A1 EP 4784121 A1 EP4784121 A1 EP 4784121A1 EP 24787545 A EP24787545 A EP 24787545A EP 4784121 A1 EP4784121 A1 EP 4784121A1
Authority
EP
European Patent Office
Prior art keywords
dmt
meo
composition
patient
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24787545.3A
Other languages
English (en)
French (fr)
Inventor
Cosmo FEILDING-MELLEN
Timothy Mason
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beckley Psytech Ltd
Original Assignee
Beckley Psytech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2314911.5A external-priority patent/GB202314911D0/en
Priority claimed from GBGB2403419.1A external-priority patent/GB202403419D0/en
Priority claimed from GBGB2403721.0A external-priority patent/GB202403721D0/en
Priority claimed from GBGB2405965.1A external-priority patent/GB202405965D0/en
Application filed by Beckley Psytech Ltd filed Critical Beckley Psytech Ltd
Publication of EP4784121A1 publication Critical patent/EP4784121A1/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP24787545.3A 2023-09-28 2024-09-27 Pharmazeutische zusammensetzungen mit 5-methoxy-n,n-dimethyltryptamin (5-meo-dmt) Pending EP4784121A1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB2314911.5A GB202314911D0 (en) 2023-09-28 2023-09-28 Dosing of 5-MeO-DMT
GBGB2403419.1A GB202403419D0 (en) 2024-03-08 2024-03-08 Dosing of 5-MeO-DMT
GBGB2403721.0A GB202403721D0 (en) 2024-03-14 2024-03-14 Dosing of 5-meo-dmt
GBGB2405965.1A GB202405965D0 (en) 2024-04-29 2024-04-29 Dosing of 5-meO-DMT
PCT/GB2024/052500 WO2025068714A1 (en) 2023-09-28 2024-09-27 Pharmaceutical compositions comprising 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt)

Publications (1)

Publication Number Publication Date
EP4784121A1 true EP4784121A1 (de) 2026-08-05

Family

ID=93061712

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24787545.3A Pending EP4784121A1 (de) 2023-09-28 2024-09-27 Pharmazeutische zusammensetzungen mit 5-methoxy-n,n-dimethyltryptamin (5-meo-dmt)

Country Status (2)

Country Link
EP (1) EP4784121A1 (de)
WO (1) WO2025068714A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL297861A (en) 2020-05-08 2023-01-01 Psilera Inc Novel compositions of matter and pharmaceutical compositions
US11312684B1 (en) 2021-02-10 2022-04-26 Eleusis Therapeutics Us, Inc. Pharmaceutically acceptable salts of psilocin and uses thereof
WO2026068953A1 (en) * 2024-09-27 2026-04-02 Beckley Psytech Limited Methods and kits comprising 5-meo-dmt for use in treating depression
WO2026068950A1 (en) * 2024-09-27 2026-04-02 Beckley Psytech Limited Pharmaceutical compositions of 5-meo-dmt for use in the treatment of alcohol use disorders
WO2026068951A1 (en) * 2024-09-27 2026-04-02 Beckley Psytech Limited 5-methoxy-dmt for use in the treatment of depression

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3007992B1 (fr) 2013-07-05 2018-01-26 Aptar France Sas Dispositif de distribution de produit fluide ou pulverulent.
HUE066828T2 (hu) * 2019-02-22 2024-09-28 Gh Res Ireland Limited 5-Metoxi-N,N-Dimetiltriptamin (5-Meo-Dmt) súlyos depressziós rendellenesség kezelésére
FR3098407B1 (fr) 2019-07-10 2024-12-13 Aptar France Sas Dispositif de distribution nasale de poudre
BR112022025306A2 (pt) * 2020-06-12 2023-02-28 Beckley Psytech Ltd Composição compreendendo um sal benzoato de 5-metóxin, n-dimetiltriptamina
GB202008961D0 (en) * 2020-06-12 2020-07-29 Beckley Psytech Ltd Pharmaceutical composition
FR3117046B1 (fr) 2020-12-09 2023-02-10 Aptar France Sas Dispositif de distribution de doses de poudre
FR3119772B1 (fr) 2021-02-15 2024-06-14 Aptar France Sas Tête de distribution pour dispositif de distribution nasale d’un produit fluide ou pulvérulent
FR3121047B1 (fr) 2021-03-29 2023-07-14 Aptar France Sas Dispositif de distribution nasale de poudre
EP4159192A1 (de) * 2021-09-30 2023-04-05 Biomind Labs Inc Nasenspray auf dimethyltriptaminbasis für die personalisierte behandlung von neurologischen und psychiatrischen störungen
GB202212116D0 (en) * 2022-08-19 2022-10-05 Beckley Psytech Ltd Pharmaceutically acceptable salts and Compositions thereof
WO2024105379A1 (en) * 2022-11-14 2024-05-23 Beckley Psytech Limited Formulations of 5-meo-dmt

Also Published As

Publication number Publication date
WO2025068714A1 (en) 2025-04-03

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20260326

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR